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Human  genetics  -  linking  inherited  variation  in  DNA 
sequence  with  traits  such  as  susceptibility  to  disease  - 
provides prima facie evidence that a gene and a pathway 
are associated with a disease. The most recent wave of 
genomic technology has allowed human genomes to be 
scanned for variant DNA sequences (or alleles) in many 
people to determine which alleles are associated with a 
particular  disease  or  phenotype  of  interest.  Termed 
genome-wide  association  studies,  or  GWASs,  this 
approach  has  identified  hundreds  of  alleles  that  are 
associated with a variety of human traits [1,2]. By most 
accounts, the GWAS approach has been very successful 
at identifying new regions of the genome (or loci) that are 
important in disease, even though the effect sizes of most 
alleles are modest.
The GWAS approach has been particularly successful 
at  uncovering  risk  alleles  for  autoimmune  diseases. 
Collectively, autoimmune diseases are common, affecting 
more than 5% of the adult population [3]. These diseases 
include rheumatoid arthritis (RA), type 1 diabetes (T1D), 
inflammatory  bowel  disease  (IBD),  systemic  lupus 
erythematosus  (SLE),  multiple  sclerosis  (MS),  psoriasis 
and  celiac  disease  (among  others).  RA  is  a  chronic 
inflam  matory  disease  that  destroys  free  moving  joints. 
T1D is a form of diabetes that results from the destruc-
tion of insulin-producing beta cells of the pancreas. IBD 
is a group of inflammatory conditions of the colon and 
small intestine; the two major types are Crohn’s disease 
and ulcerative colitis. In SLE, the immune system attacks 
a wide variety of organs, including the heart, joints, skin, 
lungs, blood vessels, liver, kidneys and nervous system. 
MS is an autoimmune disease in which the fatty myelin 
sheaths around the axons of the brain and spinal cord are 
damaged,  leading  to  a  broad  spectrum  of  signs  and 
symptoms.  Psoriasis  is  a  chronic  disease  in  which  the 
skin develops red, scaly patches, which is the result of 
areas  of  inflammation  and  excessive  skin  production. 
Celiac disease is an autoimmune disorder of the small 
intestine caused by a reaction to storage proteins (called 
glutens)  found  in  cereal  grains;  the  ensuing  excessive 
immune reaction leads to an attack on the intestinal villi 
and tissue damage, resulting in malabsorption of nutrients.
So far, approximately 150 loci have been identified that 
increase  risk  of  these  autoimmune  diseases  [4-14].  For 
each  disease,  the  strongest  genetic  risk  factors  reside 
within  the  major  histocompatibility  complex  (MHC) 
region on chromosome 6 [15]. Most associated alleles in 
other regions are common in the general population, but 
increase the disease risk by only 10 to 20% (corresponding 
to an odds ratio (OR) of 1.10 to 1.20 per copy of the risk 
allele). (The OR is a measure of the strength of association; 
it refers to the ratio of the odds of an event occurring in 
one group (such as cases) to the odds of it occurring in 
another  group  (such  as  controls).)  For  any  given  auto-
immune  disease,  the  known  genetic  risk  alleles  explain 
between 10 and 20% of variance in disease risk, whereas 
more than 50% of disease risk is estimated to be heritable. 
The remaining 30% or so of unexplained genetic disease 
risk is termed the missing heritability.
The challenges now are, first, to find the causal mutation 
responsible  for  the  signal  of  association;  second,  to 
understand which gene is disrupted by the causal mutation 
and how it is disrupted (that is, whether the mutation results 
in  gain  of  function,  loss  of  function,  or  a  new  function 
altogether);  third,  to  understand  which  cell  type  and 
biological  pathways  are  altered  by  these  mutations;  and 
finally to find additional mutations that explain the missing 
heritability [16].  The next wave  of genomic technology  - 
next-generation sequencing - will be a powerful ally in this 
effort. In particular, next-generation sequencing will help 
localize the causal mutation, as well as help identify rare 
alleles that confer risk of autoimmune disease.
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© 2010 BioMed Central LtdThus, an important question remains: what is the most 
appropriate scientific approach to understand function of 
risk alleles discovered in human genetics research? Is the 
mouse the most appropriate model organism, or do these 
genetic  discoveries  provide  new  resources  to  enable 
functional studies directly in human immune cells?
Here,  I  discuss  the  confluence  of  events  that  create  a 
unique opportunity to use human subjects as the ‘model 
organism’  for  the  study  of  autoimmune  disease  patho-
genesis.  In  addition  to  GWASs  and  next-generation 
sequencing,  registries  of  blood  draws  from  healthy, 
consenting human volunteers enable functional studies of 
genetic variants in a wide range of primary human immune 
cells, and human stem cell technology has advanced to the 
point at which induced pluripotent stem (iPS) cells can be 
derived  from  patients  with  specific  mutations  and 
differentiated into diverse immune lineages. These resources 
should allow investigators to understand the altered cellular 
state  in  diseases  that  are  uniquely  human,  which  should 
ultimately lead to new therapeutics to treat or prevent the 
devastating consequences of autoimmune disease.
Common SNPs and risk of autoimmune disease
In  general,  ‘common’  variants  are  those  present  at  a 
frequency of over 1% in any one continental population 
(such as Europeans, Asians and Africans), whereas ‘rare’ 
variants are those present at a frequency of less than 1% 
in  these  populations  [17].  This  simple  categorical 
distinction has been made in order to frame the genetic 
approach  to  discovering  and  testing  DNA  variants  for 
their role in disease. For common variants, it is possible 
to screen a reference population to identify a catalog of 
variants  (the  discovery  phase),  and  then  test  these 
variants in case-control collections using high-through-
put genotyping technologies (the testing phase). A variety 
of  resources  have  been  developed  to  catalog  common 
single nucleotide polymorphisms (SNPs), including the 
International  HapMap  Project  [17,18].  More  recently, 
data from the 1000 Genomes Project [19] have begun to 
be used to catalog variants in the 1% frequency range.
In  order  to  test  whether  these  common  SNPs  are 
associated with risk of disease, commercial ‘SNP chips’ or 
arrays have been developed that capture most, although 
not all, common variation in the genome. These geno-
typing  arrays  can  genotype  hundreds  of  thousands  of 
SNPs in a single experiment, at a cost of several hundred 
US dollars per sample. Contemporary GWASs use these 
arrays  to  measure  the  frequency  of  alleles  in  cases 
compared  with  controls.  If  the  difference  in  allele 
frequency reaches a stringent level of statistical signifi-
cance  that  corrects  for  the  fact  that  there  are  about 
1,000,000  independent  common  SNPs  in  the  human 
genome (this significance level is about P < 5 × 10-8), then 
the allele is said to be ‘associated’ with disease.
There are approximately 10 million common SNPs in 
the human genome. A fundamental challenge in human 
genetics is to systematically test each of these 10 million 
common  SNPs  for  its  role  in  disease.  Contemporary 
GWASs test several hundred thousand SNPs across the 
entire  human  genome,  most  of  which  are  common 
(minor allele frequency over 5%) in the general, healthy 
population. To test the remaining over 9 million common 
SNPs,  the  GWAS  approach  relies  on  the  correlation 
structure of nearby SNPs. That is, nine out of ten SNPs 
are highly correlated, and testing one SNP serves to tag 
the remaining nine nearby SNPs. This concept is known 
as linkage disequilibrium (LD).
The  underlying  rationale  for  the  GWAS  approach  is 
rooted  firmly  in  population  genetics,  as  most  of  the 
differences  between  any  two  chromosomes  are  due  to 
common SNPs [20]. On the basis of the hypothesis that 
disease alleles reflect the allelic spectrum of diseases in the 
general population, the risk of common diseases will be 
attributable in part to allelic variants that are also common.
GWASs  have  discovered  about  150  loci  that  harbor 
SNPs  associated  with  risk  of  autoimmune  diseases. 
Several of the earliest GWASs that successfully identified 
common risk alleles were done in autoimmune diseases. 
Crohn’s disease is an illustrative example. Before GWASs, 
only  two  loci  outside  the  MHC  were  known  to  be 
associated  with  Crohn’s  disease  risk  [21].  In  2006,  a 
GWAS of about 1,000 case-control samples identified a 
coding  variant  in  the  interleukin  23  receptor  (IL23R) 
gene  locus  [22].  The  landmark  Wellcome  Trust  Case 
Control Consortium GWAS, published in 2007, included 
three  autoimmune  diseases  (of  the  seven  diseases 
studied): Crohn’s disease, T1D and RA [23]. Since these 
initial GWASs, over 30 Crohn’s disease risk loci [7], over 
40 T1D risk loci [6] and over 25 RA risk loci have been 
discovered [24].
From these GWASs, an important theme has emerged: 
the  overlap  among  the  loci  that  confer  risk  of 
autoimmune disease. In 2008, Smyth and colleagues [9] 
studied the overlap between celiac disease and T1D. The 
study [9] found that nearly half of the about 30 risk loci 
contributed to both diseases, whereas the others seemed 
to be disease-specific. Other studies have compared and 
contrasted  risk  confirmed  alleles  for  a  variety  of 
autoimmune diseases [9,25-27]. There is clear overlap for 
many  of  the  known  risk  alleles,  consistent  with 
epidemiological data of disease clustering within families 
[28]. A partial list of loci associated with multiple auto-
immune diseases is shown in Table 1.
Missing heritability: next-generation sequencing 
and the role of rare SNPs
Although the number of loci associated with autoimmune 
disease is impressive, these loci cannot explain a sizeable 
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common alleles can only explain 5 to 10% of disease risk 
associated  with  autoimmune  disease.  Considering  that 
family  studies  have  shown  that  more  than  50%  of 
autoimmune  disease  risk  is  thought  to  be  genetic,  the 
question arises as to why so much of the heritability is 
apparently unexplained by initial GWAS findings. One of 
the  most  frequently  cited  explanations  for  ‘missing 
heritability’ is that rare SNPs contribute substantially to 
disease  risk,  and  contemporary  GWAS  arrays  do  not 
adequately capture rare variants [16].
There are two ways to test rare variants systematically 
for association with disease. First, it is possible to catalog 
low-frequency  variants  -  those  variants  present  in 
approximately 0.5 to 5% of control chromosomes - in a 
manner  analogous  to  common  variants.  The  only 
difference is that a greater number of subjects need to be 
included in the discovery effort. This is the main premise 
behind the 1000 Genomes Project [19]. Once discovered 
and  catalogued,  these  low-frequency  variants  could  be 
genotyped  in  a  high-throughput  manner  using  geno-
typing arrays.
The  second  approach  is  to  couple  the  discovery  and 
testing phases into a single experiment. That is, direct 
sequencing  is  done  in  case-control  collections  them-
selves, generating an unbiased catalog of DNA variants 
that are then tested for association with disease.
Until  recently,  direct  sequencing  in  large  patient 
samples was cost prohibitive. Next-generation sequenc-
ing has been developed to sequence large regions of DNA - 
with  the  ultimate  goal  of  sequencing  the  complete 
genome  -  in  a  high-throughput  and  cost-effective 
manner. In the near future, next-generation sequencing 
will  probably  be  the  technical  method  of  choice  for 
conducting GWASs.
From associated SNP to causal allele and causal 
gene
An important promise of human genetics is that GWASs 
offer an unbiased approach to discovering new pathways 
that cause disease. Towards this end, a major challenge is 
to  take  the  expanding  list  of  disease  risk  alleles  and 
understand the effect on gene function. The first step is 
to identify which gene near the associated SNP has its 
function  affected  by  the  underlying  causal  mutation 
(which is rarely known). This step is critical, as the region 
of  LD  surrounding  the  associated  SNP  often  contains 
more than one gene (although often there is one likely 
candidate gene from the known biology). A region of LD 
includes neighboring sequence in which a group of SNPs 
are  highly  correlated  (for  example,  at  a  correlation 
coefficient of r2 > 0.80). Moreover, it is conceivable that 
the  causal  mutation  exerts  its  effect  at  a  distance  (for 
example, by altering gene expression) or that the causal 
mutation is rare in the general population and located 
some distance from the associated SNP [29].
As shown in Figure 1, there are at least three general 
approaches to get from associated SNP to causal gene 
(and causal mutation). First, fine-mapping of the region 
of  LD  is  performed  using  resequencing  and  dense 
genotyping. An allele is considered causal if it is predicted 
to alter function and if direct experimentation demon-
strates  altered  function.  An  intriguing  result  from 
GWASs is that most associated SNPs lie outside coding 
regions, and most of the causal mutations probably also 
fall outside coding regions. It is likely that many causal 
mutations affect gene expression or mRNA splicing.
One of the best examples was fine-mapping and func-
tional studies of IRF5, a gene associated with SLE and 
other  autoimmune  diseases  [30,31].  IRF5  encodes  a 
member of the interferon regulatory factor (IRF) family, a 
group  of  transcription  factors  with  diverse  roles, 
including  virus-mediated  activation  of  interferon  and 
modulation of cell growth, differentiation, apoptosis and 
immune  system  activity.  Studies  have  revealed  three 
functional alleles of IRF5: an exon 1 splice site variant, a 
Table 1. Loci associated with multiple autoimmune 
diseases
 Chromosome  Position  Gene(s)  Disease*  References
  1  67466790  IL23R  Psoriasis, CD, UC  [7,12,53]
  1  114179091  PTPN22  SLE, CD, RA, T1D  [7,8,54,55]
  1  116905738  CD58  MS, RA  [5,11]
  1  205006527  IL10  SLE, T1D, UC  [6,8,14]
  2  102437000  IL18RAP  T1D, celiac  [9]
  2  191672878  STAT4  RA, SLE  [56]
  2  204402121  CTLA4  RA, T1D, celiac  [6,13,57]
  4  25694609  RBPJ  T1D, RA  [6]
  4  123351942  IL2   T1D, Celiac, RA, UC  [6,25,58]
  5  150437678  TNIP1  SLE, psoriasis  [8]
  5  158650367  IL12B  Psoriasis, CD  [7,12]
  6  106541962  PRDM1, ATG5  CD, RA, SLE  [5,7,8]
  6  138014761  TNFAIP3  Celiac, RA,   [12,13,59-61] 
        SLE, psoriasis
  6  159385965  TAGAP  Celiac, RA  [5,10]
  6  167357978  CCR6  CD, RA  [7]
  7  128376236  IRF5  SLE, RA  [31,62]
  8  11377591  BLK  SLE, RA  [35,63]
  10  6138955  IL2RA  RA, MS, T1D  [6,64]
  10  6430456  PRKCQ  T1D, RA  [4,65]
  16  11074189  CLEC16A  MS, T1D  [11,66]
  18  12769947  PTPN2  CD, celiac, T1D  [7,13,66]
*CD, Crohn’s disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; T1D, type 1 diabetes; UC, ulcerative colitis.
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variant  in  a  conserved  poly(A)+  signal  sequence  that 
alters the length of the 3’ untranslated region and stability 
of IRF5 mRNAs [30]. Haplotypes of these three variants 
define at least three distinct levels of risk to SLE. There is 
an  approximately  twofold  increase  in  the  level  of  risk 
between carriers of the highest and lowest risk haplotypes.
Second, candidate genes from a region of LD can be 
resequenced  to  search  for  independent,  rare  protein-
coding  mutations.  The  underlying  hypothesis  is  that  a 
true causal gene will harbor multiple risk alleles; at least 
one  of  these  might  be  common  (and  identified  by 
GWAS), whereas many others will be rare. Precedence 
for  this  hypothesis  comes  from  studies  of  Mendelian 
disorders,  for  which  disease  can  be  caused  by  many 
different  mutations  to  the  same  gene  (genetic  hetero-
geneity). In a study published in 2009 [32], the coding 
exons  of  six  genes  identified  by  GWASs  of  T1D  were 
resequenced to search for independent rare mutations. 
Two  rare  SNPs  in  the  interferon-induced  helicase  C 
domain-containing protein 1 (IFIH1) gene were identified 
that  conferred  protection  from  T1D.  IFIH1  is  a  cyto-
plasmic protein that recognizes RNA of certain viruses 
and mediates immune activation. Following infection, the 
IFIH1 protein senses the presence of viral RNA in the 
cytoplasm, triggers activation of nuclear factor (NF)-κB 
and IRF pathways and induces antiviral IFN-β response. 
The non-synonymous SNP with the strongest association, 
rs35667974  (which  causes  the  amino  acid  substitution 
Ile923Val), was observed on an estimated 3 out of 960 
case chromosomes but 24 out of 960 control chromo-
somes  (P  =  0.00004);  another  SNP,  rs35337543  (which 
affects  a  splice  donor  site),  was  observed  on  7  case 
chromosomes and 23 control chromosomes (P = 0.005). 
Both SNPs were genotyped in more than 20,000 addi-
tional case-control samples: rs35667974 was present in 
about 1% of cases and 2% of controls (P = 2.1 × 10-16) and 
rs35337543 in 1% of cases versus 1.5% of controls (P = 
1.4 × 10-4). Both mutations are predicted to be loss-of-
function  mutations,  although  why  these  mutations 
influence risk of T1D remains unknown.
The third approach is less direct, but nonetheless very 
powerful, especially when there are many loci associated 
with  risk  of  disease.  The  underlying  hypothesis  is  that 
there are a limited number of biological pathways that 
are altered to confer risk of disease and that true causal 
genes  will  be  restricted  to  those  specific  pathways. 
Examples  of  such  pathways  include  known  signaling 
pathways  (such  as  the  NF-κB  pathway  and  risk  of  RA 
[33]) or catabolic pathways (such as autophagy and risk 
of  Crohn’s  disease  [20]).  The  challenge  of  this  compu-
tational approach is to define categories of pathways, as 
our  understanding  of  many  biological  processes  is 
incomplete.  One  successful  approach  has  been  to  use 
information contained in PubMed abstracts to establish 
connections between gene loci [34]. This approach has 
been used to identify putative causal genes for RA and 
celiac  disease  [5,13].  In  the  RA  study,  three  loci  were 
identified  that  contained  the  genes  CD28,  CD2/CD58 
and PRDM1, respectively [5]. Both CD2 and CD28 are 
co-stimulatory  molecules  on  the  surface  of  T  cells. 
PRDM1  (also  known  as  BLIMP-1)  is  a  transcription 
factor  that  regulates  terminal  differentiation  of  B  cells 
into immunoglobulin-secreting plasma cells. Once these 
connections  are  established  among  risk  loci,  direct 
experimentation is still required to prove the pathways 
are critical to disease.
Resources to validate the biological effects of 
causal mutations
Once the causal gene and causal mutation(s) have been 
identified, the next major challenge is to understand the 
underlying biological pathways that lead to autoimmune 
disease. New resources now make it possible to study the 
effects  of  mutations  linked  to  autoimmune  disease 
directly in relevant human tissue.
Registries  have  now  been  established  at  academic 
medical centers to study the functional consequences of 
common genetic mutations in blood cells from healthy 
control subjects [35]. Human immune cells (such as B 
and T lymphocytes) are easily accessible through a simple 
blood draw. These immune cells are of direct relevance to 
pathogenesis of autoimmune diseases, as indicated not 
only by recent genetic studies but also by previous studies 
in  patients  with  autoimmune  diseases  [36].  Human 
immune cells derived from healthy control subjects have 
been  used  successfully  to  gain  insight  into  function  of 
common  mutations  at  several  autoimmune  genes.  A 
missense mutation in the PTPN22 gene is associated with 
several autoimmune diseases. PTPN22 encodes a protein 
tyrosine  phosphatase  that  is  expressed  in  lymphoid 
Figure 1. From associated SNP to causal gene/mutation. There 
are at least three ways to go from an associated SNP in a GWAS 
to the causal mutation(s) and causal gene. The first is to perform 
dense genotyping to identify the set of common SNPs that yield 
the strongest signal of association, followed by hypothesis-driven 
functional studies. The second is to perform deep re-sequencing 
to search for rare mutations that are independent of the common 
mutation and that alter protein function. The third is to use 
bioinformatics approaches to establish connections among genes 
across associated loci.
(1) Fine-mapping and functional
studies
(2) Re-sequence for independent
rare mutations
(3) Connections across multiple
loci 
Causal
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studies in T cells derived from healthy human partici-
pants  have  shown  that  the  PTPN22  risk  allele  alters 
secretion  of  IL2  from  T  cells  stimulated  through  the 
T-cell receptor [38]. Other autoimmune risk alleles have 
been studied in a similar manner: a common multiple 
sclerosis risk mutation at CD58 can explain about 40% of 
the  variance  of  CD58  cell  surface  expression  on 
peripheral blood mononuclear cells (PBMCs) [39]; and a 
common  T1D  mutation  in  IL2RA  alters  IL2RA  cell 
surface expression on CD4+ memory T cells [40].
Another  new  approach  is  to  generate  iPS  cells  from 
patients  who  carry  specific  genetic  mutations.  First 
described in 2006 [41], several studies have shown that 
iPS cells can be derived from patients with with Mendelian 
disorders [42]. By definition, iPS cells are pluripotent and 
can be differentiated into any human cell type. Specific 
protocols  are  required  to  direct  differentiation  into  a 
specific  cell  lineage.  In  the  case  of  immune  lineages, 
protocols  have  been  developed  to  differentiate  human 
embryonic stem (ES) cells into B cells, T cells, natural 
killer cells, and other immune lineages [43-50]. Because 
of the similarities between ES and iPS cells, differentiation 
protocols developed in ES cells should be applicable to 
differentiation  of  iPS  cells  into  these  same  immune 
lineages.
Whether  iPS  cells  derived  from  patients  with  auto-
immune disease will be useful for functional studies of 
human genetic mutations is a hypothesis that needs to be 
rigorously  tested.  Human  iPS  cells  offer  several  theo-
retical  advantages  over  primary  human  immune  cells 
derived  from  healthy  patients.  First,  although  many 
immune lineages can be isolated from peripheral blood, 
many  reside  within  lymph  nodes  and  other  privileged 
sites  not  accessible  through  the  blood.  Moreover,  it  is 
impractical to isolate more than a few immune lineages 
in the amount of blood drawn from a single individual at 
a  single  point  in  time.  Second,  in  studies  of  primary 
human  immune  cells,  it  is  important  to  investigate 
carriers and non-carriers of mutations on the same day to 
minimize  technical  variability.  iPS  cells  have  the 
theoretical advantage of repeated measurements under a 
set of controlled conditions. Finally, primary human cells 
have a limited lifespan in culture. As a consequence, it is 
difficult  to  manipulate  primary  cells  with  transfections 
and other cellular perturbations.
Most  genetic  discoveries  have  concerned  the  risk  of 
disease overall, rather than relevant subsets of disease; 
this applies not just to autoimmunity but also to other 
diseases. As a consequence, a new challenge is to corre-
late genotype with clinically relevant phenotypes, such as 
response to therapy and disease severity. For genotype-
phenotype  correlation  studies,  the  major  bottleneck  is 
setting up large registries of patients with biospecimens 
for genomic studies and detailed clinical data. Traditional 
patient registries and clinical trials - the workhorse for 
sample collection over the past decades - are unlikely to 
achieve  the  size  required  to  obtain  thousands  of 
autoimmune  patient  samples  for  these  studies.  New 
approaches - next-generation registries - will be required 
to break this bottleneck. In theory, it should be possible 
to collect data as part of routine patient care. Increased 
use  of  electronic  medical  records  [51]  and  new 
approaches to mining clinical data from such records [52] 
is one exciting approach to expanding sample collections.
Contemporary  GWASs  of  common  variants  have 
identified  approximately  150  loci  that  confer  risk  of 
common  autoimmune  diseases.  Once  the  causal  genes 
and  causal  mutations  have  been  identified,  the  next 
challenges will be to understand the underlying biological 
pathways and to correlate genotype with clinically rele-
vant  phenotypes.  New  resources  are  now  available  to 
enable  these  translational  immunology  studies  in 
humans. Over the next few years, great strides should be 
made  towards  accomplishing  these  ambitious  yet 
attainable goals.
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